Compare Illumina, Inc. (ILMN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Xylem, Inc. — how do they compare? Illumina, Inc. trades at $192.58 (market cap $29.13B), while Xylem, Inc. trades at $120.1 (market cap $28.47B). The key difference: Illumina, Inc. and Xylem, Inc. are close in size by market cap, and Xylem, Inc. pays a 1.41% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | XYL | |
|---|---|---|
Market Cap | $29.13B | $28.47B |
Sector | Health | Industrials |
52-Week High | $205.10 | $152.95 |
52-Week Low | $91.00 | $106.34 |
Enterprise Value | $30.49B | $30.25B |
Dividend Yield | — | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.64, showing minimal daily movement (-0.1%) with strong fundamental improvement. The stock maintains a neutral technical stance while demonstrating robust profitability with 66.4% gross margins and 18.3% net income margin. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $1.31 exceeding the $1.23 estimate. The company's Billion Cell Atlas expansion with AI partners signals growth potential in genomics.
ILMN presents a compelling growth story with improving financials and analyst support, though elevated valuation multiples and competitive pressures warrant caution. The consensus price target of $201.58 suggests modest upside potential from current levels, supported by 51% analyst buy ratings. Key risks include execution challenges in new initiatives and market volatility in the genomics sector.
Xylem (XYL) trades at $120.32, down 2.32% on the day, amid a bullish technical setup with moving averages supporting upward momentum. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.46 versus $1.35 expected, and raised full-year profit guidance. Revenue growth has been steady, climbing from $5.5B in 2022 to $9.0B in 2025, with net income margins improving to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to bolster its industrial water solutions portfolio.
The outlook remains positive with a consensus price target of $150.43, implying 25% upside, though risks include execution of acquisitions and potential delays in electric metering projects. Analyst sentiment is mixed with 47.5% buy ratings, but institutional activity shows both buying and selling, reflecting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
